Pseudobulbar Affect in Parkinsonian Disorders: A Review

被引:12
|
作者
Hakimi, Mathew [1 ]
Maurer, Carine W. [2 ]
机构
[1] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA
[2] SUNY Stony Brook, Sch Med, Dept Neurol, Stony Brook, NY 11794 USA
关键词
Pseudobulbar affect; Parkinson's disease; parkinsonism; PATHOLOGICAL LAUGHTER; DEXTROMETHORPHAN/QUINIDINE; STIMULATION; VALIDATION; FREQUENCY; QUINIDINE; DISEASE; REGION; SCALE; MOOD;
D O I
10.14802/jmd.18051
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Pseudobulbar affect (PBA) is a neurological symptom of inappropriate and uncontrollable laughter or crying that occurs secondary to a variety of neurological conditions, including parkinsonian disorders. PBA is a socially and emotionally debilitating symptom that has been estimated to affect 3.6% to 42.5% of the population with Parkinson's disease. While indexing measures and treatment options for PBA have been extensively studied in neurological conditions such as amyotrophic lateral sclerosis and multiple sclerosis, there has been considerably less attention given in the literature to PBA in parkinsonian disorders. The purpose of this review is to discuss the pathophysiology of PBA, its prevalence and impact on quality of life in parkinsonian disorders, and the treatment options currently available. Areas requiring further study, including the development of standardized, cross-culturally validated methods of symptom assessment, and evidence-based studies exploring the efficacy of current treatment options in parkinsonian disorders, are also highlighted.
引用
收藏
页码:14 / 21
页数:8
相关论文
共 50 条
  • [31] Identification of pseudobulbar affect symptoms in the nursing home setting: Development and assessment of a screening tool
    Allen, Carrie
    Zarowitz, Barbara
    O'Shea, Terrence
    Peterson, Edward
    Yonan, Charles
    Waterman, Fanta
    GERIATRIC NURSING, 2018, 39 (01) : 54 - 59
  • [32] Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA®) for Pseudobulbar Affect
    Pioro E.P.
    Neurology and Therapy, 2014, 3 (1) : 15 - 28
  • [33] Pseudobulbar Affect Presenting as Aggressive Behavior
    Kazi, Sana Elham
    Anwar, Adeel
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (02)
  • [34] Revisiting the pathoanatomy of pseudobulbar affect: mechanisms beyond corticobulbar dysfunction
    Bede, Peter
    Finegan, Eoin
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2018, 19 (1-2) : 4 - 6
  • [35] Pseudobulbar Affect: Burden of Illness in the USA
    Jennifer Colamonico
    Andrea Formella
    Walter Bradley
    Advances in Therapy, 2012, 29 : 775 - 798
  • [36] Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1366): : 46 - 47
  • [37] Current Concepts in the Pharmacotherapy of Pseudobulbar Affect
    Erik P. Pioro
    Drugs, 2011, 71 : 1193 - 1207
  • [38] Pseudobulbar Affect Correlates with Mood Symptoms and Low Quality of Life in Patients with Parkinson's Disease: A Comprehensive Cross-Sectional Study
    Baran, Gozde
    Totuk, Ozlem
    Yildiz, Selman
    MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL, 2024, 58 (04): : 452 - 459
  • [39] Neuromelanin in parkinsonian disorders: an update
    Martin-Bastida, Antonio
    Pietracupa, Sara
    Piccini, Paola
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2017, 127 (12) : 1116 - 1123
  • [40] Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review
    Pietracupa, Sara
    Martin-Bastida, Antonio
    Piccini, Paola
    NEUROLOGICAL SCIENCES, 2017, 38 (12) : 2095 - 2101